Baseline ̇VO2 (mL·min-1) |
1180 ± 137 |
1251 ± 119$ |
1474 ± 282* |
1522 ± 225* |
Phase II ̇VO2 time constant (s) |
24.1 ± 7.0 |
31.8 ± 5.6$ |
22.7 ± 5.6 |
28.6 ± 5.7$ |
Phase II ̇VO2 time delay (s) |
9.3 ± 5.3 |
7.4 ± 3.1 |
12.5 ± 8.5 |
9.6 ± 4.2 |
MRT ̇VO2 (s) |
33.4 ± 5.6 |
39.2 ± 3.9$ |
35.2 ± 10.5 |
38.2 ± 6.0 |
Phase II ̇VO2 amplitude (mL·min-1) |
708 ± 258 |
1659 ± 464$ |
996 ± 358 |
2032 ± 622$ |
Phase II ̇VO2 gain (mL·min-1.W-1) |
10.1 ± 1.9 |
11.6 ± 3.5 |
8.0 ± 1.5* |
8.0 ± 1.0* |
̇VO2 slow component (mL) |
|
78 ± 47 |
|
482 ± 314* |
End-exercise ̇VO2 (mL·min-1) |
1886 ± 375 |
2990 ± 561$ |
2513 ± 536* |
4035 ± 984$* |
End-exercise ̇VO2 gain (mL·min-1.W-1) |
10.0 ± 2.2 |
12.1 ± 3.6 |
8.4 ± 1.8* |
9.8 ± 1.4$* |